Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 19/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14737054 | 0.92 | SYK (0.45) | SYKKCNH2CYP2C9CYP2D6 | |
| SCHEMBL14752854 | 0.90 | SYK (0.61) | SYKKCNH2CYP2C9CYP2D6JAK2 | |
| SCHEMBL14738283 | 0.90 | SYK (0.58) | SYKKCNH2CYP2C9CYP2D6 | |
| SCHEMBL14751500 | 0.89 | SYK (0.52) | SYKKCNH2CYP2C9CYP2D6JAK2 | |
| SCHEMBL14738313 | 0.83 | SYK (0.43) | SYKKCNH2CYP2C9CYP2D6 | |
| SCHEMBL14737403 | 0.83 | SYK (0.36) | SYK | |
| SCHEMBL14737250 | 0.81 | SYK (0.45) | SYKKCNH2CYP2C9CYP2D6 | |
| SCHEMBL14751498 | 0.81 | SYK (0.47) | SYKKCNH2CYP2C9CYP2D6JAK2 | |
| SCHEMBL14737885 | 0.80 | SYK (0.60) | SYKKCNH2CYP2C9CYP2D6 | |
| SCHEMBL14751743 | 0.80 | SYK (0.44) | SYKKCNH2CYP2C9CYP2D6JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | SYK 1/4885KCNH2 3389/4885CYP2C9 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.